Our discovery that mTORC1 signaling, protein synthesis, and mitochondrial OXPHOS are increased in SETD2-deficient tumors suggested that these processes may drive cell proliferation and thus offer therapeutic susceptibilities for SETD2-mutant cancers. Here, SETD2 is linked to cancer.